Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AKBA
- Price
- 3.68
- Stock movement up
- +0.07 (2.24%)
- Company name
- Akebia Ther
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 845.81M
- Ent value
- 1.07B
- Price/Sales
- 4.98
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 12.27
- PEG
- -
- EPS growth
- -25.76%
- 1 year return
- 114.09%
- 3 year return
- 97.09%
- 5 year return
- -21.25%
- 10 year return
- -8.22%
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
AKBA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 199.11 |
| EV to EBITDA | 251.73 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 4.98 |
| Price to Book | - |
| EV to Sales | 6.29 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 265.14M |
| EPS (TTM) | -0.22 |
| FCF per share (TTM) | -0.18 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 169.88M |
| Gross profit (TTM) | 107.24M |
| Operating income (TTM) | -34.73M |
| Net income (TTM) | -45.99M |
| EPS (TTM) | -0.22 |
| EPS (1y forward) | 0.26 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 63.13% |
| Operating margin (TTM) | -20.45% |
| Profit margin (TTM) | -27.07% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 34.02M |
| Net receivables | 32.17M |
| Total current assets | 100.12M |
| Goodwill | 59.04M |
| Intangible assets | 9.01M |
| Property, plant and equipment | 0.00 |
| Total assets | 207.14M |
| Accounts payable | 13.49M |
| Short/Current long term debt | 48.58M |
| Total current liabilities | 65.71M |
| Total liabilities | 257.54M |
| Shareholder's equity | -50.40M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -38.50M |
| Capital expenditures (TTM) | 58.00K |
| Free cash flow (TTM) | -38.56M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -22.20% |
| Return on Invested Capital | 101.95% |
| Cash Return on Invested Capital | 85.47% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.12 |
| Daily high | 3.20 |
| Daily low | 3.10 |
| Daily Volume | 2.93M |
| All-time high | 29.17 |
| 1y analyst estimate | 7.40 |
| Beta | 0.96 |
| EPS (TTM) | -0.22 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 Nov 2025 |
Downside potential
Loading...
Downside potential data
| AKBA | S&P500 | |
| Current price drop from All-time high | -89.06% | -1.46% |
| Highest price drop | -99.14% | -56.47% |
| Date of highest drop | 29 Nov 2022 | 9 Mar 2009 |
| Avg drop from high | -76.08% | -10.99% |
| Avg time to new high | 411 days | 12 days |
| Max time to new high | 2810 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
845.81M
Marketcap category
Small-cap
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Employees
181
Website
Investor relations
-
SEC filings
CEO
John P. Butler
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page